Actively Recruiting
STabilization of Atheroma by Lipid-reducing Effect of Drug-Coated Balloon (STABLE-DCB)
Led by Korea University Ansan Hospital · Updated on 2024-10-15
65
Participants Needed
1
Research Sites
220 weeks
Total Duration
On this page
Sponsors
K
Korea University Ansan Hospital
Lead Sponsor
B
B. Braun Korea Co., Ltd.
Collaborating Sponsor
AI-Summary
What this Trial Is About
This study aims to investigate whether DCB angioplasty, compared to statin-based medical treatment alone, will lead to more reduction in plaque lipid burden as assessed by near infrared spectroscopy (NIRS) at 6-9 months following the index procedure.
CONDITIONS
Official Title
STabilization of Atheroma by Lipid-reducing Effect of Drug-Coated Balloon (STABLE-DCB)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with significant multivessel coronary artery disease requiring revascularization
- Any de novo lesions with reference vessel diameter of 2.25mm to 4.0mm suitable for DCB angioplasty
- Lesion suitable for intravascular imaging
- Written informed consent
You will not qualify if you...
- Hemodynamically unstable or cardiogenic shock
- Left main stenotic lesion or graft vessel lesion
- Visible angiographic thrombus not resolved by balloon angioplasty
- Pregnancy or breastfeeding
- Comorbidities with life expectancy less than 12 months
- Severe coronary calcification or tortuosity hindering timely DCB delivery
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Korea University Ansan Hospital
Ansan-si, Gyeonggi-do, South Korea, 15355
Actively Recruiting
Research Team
S
Sunwon Kim, MD, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here